Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Capital Expenditures (2016 - 2025)

Sonoma Pharmaceuticals has reported Capital Expenditures over the past 16 years, most recently at $47000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 2250.0% year-over-year to $47000.0; the TTM value through Dec 2025 reached $210000.0, up 1300.0%, while the annual FY2025 figure was $80000.0, 3900.0% up from the prior year.
  • Capital Expenditures for Q4 2025 was $47000.0 at Sonoma Pharmaceuticals, up from $10000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $190000.0 in Q1 2023 and troughed at -$18000.0 in Q1 2024.
  • A 5-year average of $32800.0 and a median of $24000.0 in 2021 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: surged 3000.0% in 2022 and later crashed 109.47% in 2024.
  • Year by year, Capital Expenditures stood at $1000.0 in 2021, then surged by 3000.0% to $31000.0 in 2022, then crashed by 96.77% to $1000.0 in 2023, then surged by 100.0% to $2000.0 in 2024, then surged by 2250.0% to $47000.0 in 2025.
  • Business Quant data shows Capital Expenditures for SNOA at $47000.0 in Q4 2025, $10000.0 in Q3 2025, and $106000.0 in Q2 2025.